We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...

In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager ...

Excalipoint Therapeutics, a clinical-stage biotechnology company advancing novel T-cell engager (TCE) therapies for solid tumors and autoimmune disorders, today announced a clinical collaboration with ...

Lung cancer remains the leading cause of cancer-related mortality worldwide. Although small cell lung cancer (SCLC) accounts for a smaller percentage of lung cancer cases, it has remained a ...

Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore complementary immuno-oncology mechanisms in extensive‑stage small ...

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment ...

Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, announced a clinical trial collaboration with BioNTech to evaluate a novel immuno-oncology combination in ...